Date Added: 20/03/2017
Date Updated: 20/03/2017
Ipilimumab (Yervoy) for unresectable malignant melanoma in paediatric patients
Specialties: Oncology & radiotherapy
Technology Type: Drugs
Stage of development: Experimental - pilot or phase II
Stage of EAA: Prioritised for assessment
Paediatric patients (aged 12 to <18 years old).
Stage of disease
Unresectable stage III/IV.
Place in Treatment
First line or previously treated.